Clinical Efficacy of Istradefylline for Depression in Parkinsonâs Disease

  title={Clinical Efficacy of Istradefylline for Depression in Parkinson{\^a}s Disease},
  author={H. Ito and Shigeru Fukutake and Sanae Odake and Junya Kawada and S. Iwanaga and Tetsumasa Kamei},
  journal={Journal of Neurology and Neuroscience},
  • H. Ito, Shigeru Fukutake, +3 authors Tetsumasa Kamei
  • Published 2018
  • Medicine
  • Journal of Neurology and Neuroscience
  • Background: Parkinson’s disease (PD) is a common movement disorder with a wide range of non-motor symptoms. Depression is one of these symptoms; however, its pathomechanism and management remains to be elucidated. We evaluated of istradefylline (ISD), a first selective adenosine A2A receptor antagonist, for the treatment of depression in PD. Method: This was an open-labeled, prospective study that enrolled 15 PD patients (Men 8, Women 7) with motor fluctuations who fully filled UK PD society… CONTINUE READING


    Publications referenced by this paper.
    Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
    • 171
    Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease
    • 1
    • Open Access
    Systematic review of levodopa dose equivalency reporting in Parkinson's disease
    • 2,234
    • Open Access
    Parkinson’s disease: clinical features and diagnosis
    • 3,176
    • Open Access
    The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review.
    • 1,640
    • Highly Influential
    • Open Access
    Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease
    • 126
    • Open Access